Dynamic In Vivo Size & Shape Measurement Of The Human Upper Airway Using Endoscopic Long-range Optical Coherence Tomogra
Funder
National Health and Medical Research Council
Funding Amount
$184,250.00
Summary
This project will fund the construction of a clinically deployable prototype device to measure changes in upper airway size and shape in patients with obstructive sleep apnoea. We have recently developed and validated a technique based on endoscopic optical coherence tomography (OCT). Preliminary in vivo studies have been performed in the human upper airway and the results published. To our knowledge, this is the only such system world-wide capable of making these important measurements. The tec ....This project will fund the construction of a clinically deployable prototype device to measure changes in upper airway size and shape in patients with obstructive sleep apnoea. We have recently developed and validated a technique based on endoscopic optical coherence tomography (OCT). Preliminary in vivo studies have been performed in the human upper airway and the results published. To our knowledge, this is the only such system world-wide capable of making these important measurements. The technique has wide commercially applicability as it can be used to measure the internal dimensions of any hollow organ system.Read moreRead less
Development Of Quantitative Tools For Assessment Of Regional Cardiac Function By Echocardiography
Funder
National Health and Medical Research Council
Funding Amount
$209,430.00
Summary
The application of ultrasound imaging to the assessment of cardiac function (echocardiography) is an invaluable tool for the assessment of patients with known or suspected cardiac problems. The assessment of contraction in each region of the heart is probably the most important of the reasons for doing this test, as regional function is disturbed in patients with coronary artery disease, which is one of the most common causes of death in Australia. The problem is that this analysis is currently ....The application of ultrasound imaging to the assessment of cardiac function (echocardiography) is an invaluable tool for the assessment of patients with known or suspected cardiac problems. The assessment of contraction in each region of the heart is probably the most important of the reasons for doing this test, as regional function is disturbed in patients with coronary artery disease, which is one of the most common causes of death in Australia. The problem is that this analysis is currently completely subjective, and the reliability of the tool is based upon the availability of an experienced observer. This is particularly a problem in rural Australia, as most specialists with expertise in this modality work in the capital cities, and especially a problem in Queensland, where fewer than half of the population live in the capital. The cardiac imaging group at the University of Queensland have been working in collaboration with GE-Vingmed Ultrasound to develop a quantitative technique for the assessment of regional cardiac function since 1997. This collaboration has been the source of a number of published papers and presentations at international meetings. Our group is considered to be a world leader in the field and our industry partner is clearly the most focused of its competitors in addressing this problem. This submission seeks to address several remaining problems. The data thus far addressed function during stress, when the condition of most patients is similar. Tissue velocities are more variable at rest, and a more sophisticated approach is required to accurately measure the lower velocities in the resting state. This research plan seeks support for the development of a new, high frame-rate acquisition that would facilitate the examination of velocities relative to each other, so that translational motion of the heart does not influence the reading. This new method would then be validated against other techniques for assessing function and disease.Read moreRead less
Development Of An Assay To Distinguish Between Recent And Established HIV-1 Infection
Funder
National Health and Medical Research Council
Funding Amount
$192,500.00
Summary
We have discovered a marker of recent HIV infection. Further refinement of this assay and fully evaluating it on samples from individuals infected with different subtypes of the virus will result in an HIV incidence assay ready for commercialisation. An assay capable of distinguishing between recently acquired and established HIV infection would be most valuable in establishing the incidence of infection for epidemiological surveys, to clearly identify new infections following vaccine trials and ....We have discovered a marker of recent HIV infection. Further refinement of this assay and fully evaluating it on samples from individuals infected with different subtypes of the virus will result in an HIV incidence assay ready for commercialisation. An assay capable of distinguishing between recently acquired and established HIV infection would be most valuable in establishing the incidence of infection for epidemiological surveys, to clearly identify new infections following vaccine trials and identify HIV infection as opposed to transfer of maternal antibodies in new born infants.Read moreRead less
Modulating Immune Responses By Targeting Dendritic Cells Using Dendritic Cell Specific Markers.
Funder
National Health and Medical Research Council
Funding Amount
$197,750.00
Summary
The ability to modulate immune responses would have major health benefits. Dendritic cells (DC) are key regulators of the immune system. Different types of DC possess different cell surface molecules and have differing regulatory functions. We have identified four novel DC surface molecules that can be used to target different types of DC. We aim to use antibodies against these molecules to either enhance the effectiveness of vaccines or to suppress autoimmune diseases.
Despite recent advances in therapeutic options, chronic viral infections, including infection with hepatitis C virus and hepatitis B virus, continue to be a significant cause of morbidity and mortality in Australia and affecting hundreds of millions of people worldwide. This R&D program aims to develop a cheaper drug formulation that is easier to deliver and more stable for transport to remote areas.
Cellular And Molecular Mechanisms Of Transcutaneous Immunisation
Funder
National Health and Medical Research Council
Funding Amount
$190,490.00
Summary
Vaccines are among the most effective medical interventions. The recent discovery that cholera toxin, when applied to the normal skin of humans and laboratory animals, stimulates powerful and protective immune responses to itself, and to other proteins has opened up the possibility of needle-free vaccines in the form of skin patches. How CT brings about this effect is currently unknown. We have discovered that the immune stimulating effect of CT depends upon the production of an immune protein ( ....Vaccines are among the most effective medical interventions. The recent discovery that cholera toxin, when applied to the normal skin of humans and laboratory animals, stimulates powerful and protective immune responses to itself, and to other proteins has opened up the possibility of needle-free vaccines in the form of skin patches. How CT brings about this effect is currently unknown. We have discovered that the immune stimulating effect of CT depends upon the production of an immune protein (cytokine) called tumour necrosis factor (TNF). TNF is known to activate specialised immune cells within the skin (Langerhan's Cells ) and we hypothesise that the interaction beween CT and LC via TNF is the pathway to the potent immune response. In this project we propose to investigate the cells and molecules involved in the immune effects of CT in the skin with a view to the development of new skin based vaccine strategies.Read moreRead less
Novel Vaccine Formulation For Immunotherapy Of Adenocarcinomas
Funder
National Health and Medical Research Council
Funding Amount
$178,400.00
Summary
We have designed a vaccine based on a unique delivery system. Mice immunised with vaccine were protected from a tumour challenge. We will now design a vacine with a cancer associated protein so that people once immunised can make killer cells. Since humans have different genetic makeup we will produce a vacine which is more effective and will benefit everyone. This vaccine will be more effective than a current vacine in that has yielded promising results in humans.